Bacteriophage undoubtedly work against bacterial disease and APHB is the only public company in the space.
APHB has survived so far by a combination of public funding and expanded access studies. The problem is whether management can come up with enough capital to run (a) pivotal study(ies).
Q1/18 Cash = $8.2mn while expenses totaled ~$5mn
In 2018 alone, APHB has announced cooperative programs with Veterans Administration, NIH and a government agency in Australia.
APHB is on my permanent watchlist for scalps and momentum technical patterns.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.